Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382777295> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4382777295 endingPage "588" @default.
- W4382777295 startingPage "581" @default.
- W4382777295 abstract "Research focused on lipid-lowering treatments has led to the development of new therapeutic options aimed at cardiovascular risk reduction. Gene silencing represents one of the most innovative approaches to reduce low-density lipoprotein cholesterol (LDL-C). Inclisiran is a small interfering RNA that inhibits proprotein convertase subtilisin/kexin type 9 synthesis and promotes LDL-C clearance by enhancing LDL-C receptor expression on hepatocyte cell surface. Several clinical studies have demonstrated inclisiran efficacy in terms of LDL-C reduction (~50%) with a dosage regimen of 300 mg administered twice a year after the first two doses administered at time 0 and after 90 days. Inclisiran use has recently been approved by the European and American drug regulatory agencies as a therapeutic option in addition to the maximum tolerated statin therapy in adults with primary hypercholesterolemia or mixed dyslipidemia who need further LDL-C reduction." @default.
- W4382777295 created "2023-07-02" @default.
- W4382777295 creator A5015882454 @default.
- W4382777295 creator A5036242827 @default.
- W4382777295 creator A5036360168 @default.
- W4382777295 creator A5038754045 @default.
- W4382777295 creator A5053891335 @default.
- W4382777295 creator A5053905470 @default.
- W4382777295 creator A5054052272 @default.
- W4382777295 creator A5059166446 @default.
- W4382777295 creator A5061010242 @default.
- W4382777295 creator A5065053773 @default.
- W4382777295 creator A5065677991 @default.
- W4382777295 creator A5068319384 @default.
- W4382777295 creator A5068562796 @default.
- W4382777295 creator A5081676409 @default.
- W4382777295 creator A5085026480 @default.
- W4382777295 creator A5091488991 @default.
- W4382777295 date "2023-07-01" @default.
- W4382777295 modified "2023-09-25" @default.
- W4382777295 title "[ANMCO Position paper: Inclisiran: an innovative therapeutic approach for the clinical management of hypercholesterolemia]." @default.
- W4382777295 doi "https://doi.org/10.1714/4060.40437" @default.
- W4382777295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37392123" @default.
- W4382777295 hasPublicationYear "2023" @default.
- W4382777295 type Work @default.
- W4382777295 citedByCount "0" @default.
- W4382777295 crossrefType "journal-article" @default.
- W4382777295 hasAuthorship W4382777295A5015882454 @default.
- W4382777295 hasAuthorship W4382777295A5036242827 @default.
- W4382777295 hasAuthorship W4382777295A5036360168 @default.
- W4382777295 hasAuthorship W4382777295A5038754045 @default.
- W4382777295 hasAuthorship W4382777295A5053891335 @default.
- W4382777295 hasAuthorship W4382777295A5053905470 @default.
- W4382777295 hasAuthorship W4382777295A5054052272 @default.
- W4382777295 hasAuthorship W4382777295A5059166446 @default.
- W4382777295 hasAuthorship W4382777295A5061010242 @default.
- W4382777295 hasAuthorship W4382777295A5065053773 @default.
- W4382777295 hasAuthorship W4382777295A5065677991 @default.
- W4382777295 hasAuthorship W4382777295A5068319384 @default.
- W4382777295 hasAuthorship W4382777295A5068562796 @default.
- W4382777295 hasAuthorship W4382777295A5081676409 @default.
- W4382777295 hasAuthorship W4382777295A5085026480 @default.
- W4382777295 hasAuthorship W4382777295A5091488991 @default.
- W4382777295 hasConcept C126322002 @default.
- W4382777295 hasConcept C18150654 @default.
- W4382777295 hasConcept C2778096610 @default.
- W4382777295 hasConcept C2778163477 @default.
- W4382777295 hasConcept C2778824825 @default.
- W4382777295 hasConcept C2778849439 @default.
- W4382777295 hasConcept C2779120738 @default.
- W4382777295 hasConcept C2780035454 @default.
- W4382777295 hasConcept C2780072125 @default.
- W4382777295 hasConcept C2780948078 @default.
- W4382777295 hasConcept C43554185 @default.
- W4382777295 hasConcept C511355011 @default.
- W4382777295 hasConcept C71924100 @default.
- W4382777295 hasConcept C98274493 @default.
- W4382777295 hasConceptScore W4382777295C126322002 @default.
- W4382777295 hasConceptScore W4382777295C18150654 @default.
- W4382777295 hasConceptScore W4382777295C2778096610 @default.
- W4382777295 hasConceptScore W4382777295C2778163477 @default.
- W4382777295 hasConceptScore W4382777295C2778824825 @default.
- W4382777295 hasConceptScore W4382777295C2778849439 @default.
- W4382777295 hasConceptScore W4382777295C2779120738 @default.
- W4382777295 hasConceptScore W4382777295C2780035454 @default.
- W4382777295 hasConceptScore W4382777295C2780072125 @default.
- W4382777295 hasConceptScore W4382777295C2780948078 @default.
- W4382777295 hasConceptScore W4382777295C43554185 @default.
- W4382777295 hasConceptScore W4382777295C511355011 @default.
- W4382777295 hasConceptScore W4382777295C71924100 @default.
- W4382777295 hasConceptScore W4382777295C98274493 @default.
- W4382777295 hasIssue "7" @default.
- W4382777295 hasLocation W43827772951 @default.
- W4382777295 hasOpenAccess W4382777295 @default.
- W4382777295 hasPrimaryLocation W43827772951 @default.
- W4382777295 hasRelatedWork W2014763322 @default.
- W4382777295 hasRelatedWork W2029459374 @default.
- W4382777295 hasRelatedWork W2083941082 @default.
- W4382777295 hasRelatedWork W2099136586 @default.
- W4382777295 hasRelatedWork W2258338427 @default.
- W4382777295 hasRelatedWork W2587626234 @default.
- W4382777295 hasRelatedWork W2739969222 @default.
- W4382777295 hasRelatedWork W2776490513 @default.
- W4382777295 hasRelatedWork W2788460204 @default.
- W4382777295 hasRelatedWork W4382777295 @default.
- W4382777295 hasVolume "24" @default.
- W4382777295 isParatext "false" @default.
- W4382777295 isRetracted "false" @default.
- W4382777295 workType "article" @default.